A systematic review of flurbiprofen 8.75 mg dose and risk of adverse events (excluding haemorrhagic) resulting from drug-drug interactions

A systematic review of flurbiprofen 8.75 mg dose and risk of adverse events (excluding haemorrhagic) resulting from drug-drug interactions

Background: Flurbiprofen 8.75 mg lozenges and oromucosal sprays are used for symptomatic relief of sore throat in patients aged 12 years and over. The documented adverse events of flurbiprofen use include those related to its pharmacological actions, namely, increased risk of haemorrhagic events, ho...

Full description

Bibliographic Details
Main Authors: Alison Evans, Debabrata Roy, Sandeep Dhanda, Samantha Lane, Graça Coutinho, Anuradha Kulasekaran, David Miller-Shakesby, Nagalakshmi Ramamoorthi, Saad Shakir
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-03-01
Series:Frontiers in Pharmacology
Subjects:
flurbiprofen
lozenge
oromucosal spray
drug-drug interactions
adverse events
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1107185/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2024.1107185/full

Similar Items